287 related articles for article (PubMed ID: 23299464)
21. The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Wei W; Chen X; Ma X; Wang D; Guo Z
J Neurooncol; 2015 Nov; 125(2):339-49. PubMed ID: 26334318
[TBL] [Abstract][Full Text] [Related]
22. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
23. Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Lashkari HP; Saso S; Moreno L; Athanasiou T; Zacharoulis S
J Neurooncol; 2011 Nov; 105(2):135-47. PubMed ID: 21748491
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
[TBL] [Abstract][Full Text] [Related]
25. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Abacioglu U; Caglar HB; Yumuk PF; Akgun Z; Atasoy BM; Sengoz M
J Neurooncol; 2011 Jul; 103(3):585-93. PubMed ID: 20878446
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Han SJ; Rolston JD; Molinaro AM; Clarke JL; Prados MD; Chang SM; Berger MS; DeSilva A; Butowski NA
Neuro Oncol; 2014 Sep; 16(9):1255-62. PubMed ID: 24670608
[TBL] [Abstract][Full Text] [Related]
28. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Minniti G; Scaringi C; De Sanctis V; Lanzetta G; Falco T; Di Stefano D; Esposito V; Enrici RM
J Neurooncol; 2013 Jan; 111(2):187-94. PubMed ID: 23129347
[TBL] [Abstract][Full Text] [Related]
29. Rechallenge with temozolomide in recurrent glioma.
Gaviani P; Silvani A; Lamperti E; Botturi A; Fariselli L; Simonetti G; Ferrari D; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S247-9. PubMed ID: 21987286
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of temozolomide in children with recurrent high-grade glioma.
Ruggiero A; Cefalo G; Garré ML; Massimino M; Colosimo C; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mazzarella G; Caldarelli M; Di Rocco C; Madon E; Abate ME; Clerico A; Sandri A; Riccardi R
J Neurooncol; 2006 Mar; 77(1):89-94. PubMed ID: 16292488
[TBL] [Abstract][Full Text] [Related]
31. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
32. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide in children with progressive low-grade glioma.
Gururangan S; Fisher MJ; Allen JC; Herndon JE; Quinn JA; Reardon DA; Vredenburgh JJ; Desjardins A; Phillips PC; Watral MA; Krauser JM; Friedman AH; Friedman HS
Neuro Oncol; 2007 Apr; 9(2):161-8. PubMed ID: 17347491
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
35. Rechallenge temozolomide in glioma: A case series from India.
Patil VM; Tonse R; Kothari R; Chandrasekaran A; Pande N; Epari S; Gupta T; Jalali R
Indian J Cancer; 2017; 54(1):368-371. PubMed ID: 29199725
[TBL] [Abstract][Full Text] [Related]
36. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Conti A; Pontoriero A; Arpa D; Siragusa C; Tomasello C; Romanelli P; Cardali S; Granata F; De Renzis C; Tomasello F
Acta Neurochir (Wien); 2012 Feb; 154(2):203-9. PubMed ID: 21984132
[TBL] [Abstract][Full Text] [Related]
38. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
[TBL] [Abstract][Full Text] [Related]
39. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Combs SE; Bischof M; Welzel T; Hof H; Oertel S; Debus J; Schulz-Ertner D
J Neurooncol; 2008 Sep; 89(2):205-10. PubMed ID: 18461281
[TBL] [Abstract][Full Text] [Related]
40. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
